ZGR combo for newly diagnosed spleen lymphoma with large cells
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people newly diagnosed with splenic B-cell lymphoma that has large cells (prominent nucleoli). The goal is to see if this drug combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old
- You have been diagnosed with splenic B-cell lymphoma with large cells and need treatment
- You have not had any previous treatment for this lymphoma
- Your overall health is good (able to care for yourself and up and about about half the day)
- Your kidney and liver function are within certain limits, and your blood cell counts are high enough
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) for people with a specific high-risk form of follicular lymphoma who have not yet been treated. The goal is to see if this combination can control the lymphoma more effectively.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
Hear when a new Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.